Dianthus Therapeutics (NASDAQ:DNTH) Trading Down 6.8% – Here’s Why

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) shares fell 6.8% during trading on Tuesday . The stock traded as low as $25.04 and last traded at $25.21. 156,085 shares were traded during trading, a decline of 55% from the average session volume of 344,286 shares. The stock had previously closed at $27.04.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. TD Cowen initiated coverage on shares of Dianthus Therapeutics in a report on Friday, December 20th. They issued a “buy” rating for the company. Raymond James upgraded Dianthus Therapeutics to a “moderate buy” rating in a report on Thursday, December 12th. Oppenheimer lifted their price objective on Dianthus Therapeutics from $48.00 to $52.00 and gave the stock an “outperform” rating in a report on Monday, November 11th. Finally, HC Wainwright restated a “buy” rating and issued a $40.00 price target on shares of Dianthus Therapeutics in a research report on Monday, November 11th. Eight analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $46.43.

Dianthus Therapeutics Trading Down 0.1 %

The firm has a market capitalization of $757.09 million, a price-to-earnings ratio of -10.23 and a beta of 1.74. The business has a 50-day moving average price of $24.61 and a two-hundred day moving average price of $26.59.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.15). The firm had revenue of $2.17 million for the quarter, compared to the consensus estimate of $1.07 million. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. On average, equities research analysts predict that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Janus Henderson Group PLC grew its position in Dianthus Therapeutics by 40.5% in the third quarter. Janus Henderson Group PLC now owns 949,334 shares of the company’s stock valued at $25,936,000 after acquiring an additional 273,670 shares during the period. State Street Corp increased its position in shares of Dianthus Therapeutics by 101.4% during the 3rd quarter. State Street Corp now owns 821,131 shares of the company’s stock worth $22,483,000 after purchasing an additional 413,425 shares in the last quarter. Great Point Partners LLC lifted its holdings in Dianthus Therapeutics by 21.3% during the 2nd quarter. Great Point Partners LLC now owns 757,929 shares of the company’s stock valued at $19,615,000 after purchasing an additional 132,929 shares during the last quarter. Braidwell LP boosted its position in Dianthus Therapeutics by 34.6% in the third quarter. Braidwell LP now owns 493,687 shares of the company’s stock valued at $13,517,000 after buying an additional 126,836 shares in the last quarter. Finally, Point72 Asset Management L.P. grew its stake in Dianthus Therapeutics by 151.3% during the third quarter. Point72 Asset Management L.P. now owns 437,700 shares of the company’s stock worth $11,984,000 after buying an additional 263,500 shares during the last quarter. 47.53% of the stock is currently owned by institutional investors and hedge funds.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.